English Site Index › AI4S Case · English
Provec is the latest AI for Science / AI for Medicine case of Pooling Medicine / 100Biotech: starting from the synthetic transfer vehicle STV-C8 (Nature, Sept 2026, Helmholtz Centre), it uses the newest AI protein-design toolchain (RFdiffusion + ProteinMPNN + AlphaFold3 / Chai-1) to systematically redesign every module — full optimization, patent design-around, and shortcoming completion — targeting in-vivo CAR-T, in-vivo T-cell engagers and CRISPR combination therapy.
Safety, efficacy and accessibility are hard to achieve together. Lentiviral vectors: near-100% ex-vivo CAR-T transduction but integration risk and very high cost. LNP: safe and cheap but >95% of mRNA is trapped in endosomes and liver tropism limits extra-hepatic delivery. STV-C8 proved a "fourth option": a four-module fusion protein budding from HEK293T cells into ~110 nm vesicles that fuse with the target membrane, delivering RNA directly into the cytoplasm — >1,000× the transfection efficiency of LNP and >10,000× less RNA dose.
| Dimension | STV-C8 (Nature 2026) | Provec (Pooling Medicine) |
|---|---|---|
| Protein scaffold | HE0690, first-batch RFdiffusion C8 assembly, Tm ~65°C | New C8/D3 assembly library, Tm >80°C, <30% sequence identity, patent design-around |
| Membrane-binding domain | UaPHPLC (black-bear heterologous PH domain) | Humanized / human PH domain, immunogenicity −90% |
| RNA packaging | Single-copy PP7, linear mRNA 3–7 days | Multi-copy PP7, circRNA/saRNA 2–4 weeks, payload 5–10× |
| Targeting | VSV-G mutant + monovalent minibinder | Multivalent minibinder array + AND-gate logic gating, precision 100× |
| Backbone plasmid | Standard pCAG | Optimized promoter + WPRE, expression 3–5× |
| Transfection reagent | JetOptimus (commercial) | In-house poly(β-amino ester): DNA −50%, titer 3–5×, cost −80% |
| IP | Protected by WO2026068725A1 | Fully independent, autonomous IP |
| Overall | Baseline | Delivery efficiency 10–50×, production cost −80%+ |
These are pre-experimental design targets derived from public literature and AI-assisted research; experimental validation is being planned.
Three stages over ~36 months: basic optimization (6–12 mo), differentiated breakthrough (12–24 mo), full surpassing and IND-enabling (24–36 mo).
Email a cooperation inquiry Full Chinese case page 100Biotech wet-lab validation services (EN)
An AI for Science redesigned next-generation synthetic RNA delivery platform by Pooling Medicine, based on STV-C8 (Nature 2026) with nine-dimension optimization, patent design-around and independent IP.
It uses membrane fusion rather than endosomal uptake (no endosome trap) and has no genomic integration risk, allowing repeat dosing and programmable targeting.
Clinical, technical, and industry/capital partners are invited. Use the Inquiry float on any page or email wendy@100biotech.com with your organization, field and role.
Every page on both Chinese websites has an English counterpart. The PoolingMed logo float at the bottom right of every page links to this complete English site index; the Inquiry float lets you send a structured cooperation request by email.